Eli Lilly (LLY) Stock: Company Sues Six Firms Over Black-Market Weight-Loss Drug
TLDR
- Eli Lilly has filed six lawsuits against U.S. companies selling black-market versions of its experimental obesity drug, retatrutide
- Retatrutide is still in Phase 3 clinical trials and has not been approved by the FDA for human use
- The defendants include compounding pharmacies, medical spas, and online sellers
- U.S. Customs and Border Protection intercepted over 1,400 shipments of illicit GLP-1 drugs in July alone, nearly 90,000 vials
- Lilly has referred more than 200 individuals and entities to federal and state law enforcement agencies
Eli Lilly (LLY) is taking legal action against six U.S. companies it says are illegally selling black-market versions of its experimental weight-loss drug retatrutide. LLY stock was trading down 0.68% on Wednesday.
The lawsuits target Aesthetic Envy Cosmetic Centers, Astra, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide. The defendants span a range of business types, including compounding pharmacies, medical spas, and online resellers.
โฆ Continue reading the full article at the original source below.
This content is automatically aggregated. Full credit goes to the original publisher (coincentral.com).
